Protalix BioTherapeutics (PLX) - Dhuwit awis saben saham

protalix.com - logo grafis emiten PLX

Protalix BioTherapeutics (PLX) revenues rely on a single drug for Fabry disease, creating a single-product risk. The cash per share metric provided by GURU.Markets shows a value of 0.59. The company utilizes its unique ProCellEx platform for low-cost protein synthesis in plants, while royalties from Elfabrio ensure a steady stream of high-margin free cash flow.

PLX (Protalix BioTherapeutics Inc.) riwayat Dana dhuwit saben saham saka 04.07.2022 nganti 20.11.2026

Rincian analitis perusahaan Protalix BioTherapeutics (PLX)

- nilai saham lan prakiraan konsensus rega:
- indikator anane dhuwit lan arus kas:
Ringkesan analisis perusahaan:PLX, Protalix BioTherapeutics, Inc
Produk asli Protalix BioTherapeutics, Inc

This metric reflects the share of net liquid assets per common share, allowing for an assessment of the security's intrinsic value and the issuer's financial strength. By analyzing the cash per share trend, an investor can compare the rate of capital burn with the development of the unique plant-based platform of Protalix BioTherapeutics (PLX) within high-yield rare disease therapy niches.